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Abstract: Fexofenadine (FEX) has high solubility and low permeability (BCS, Class III). 
In this work, novel FEX loaded water in oil microemulsion (w/o) was designed to improve 
  bioavailability and compared with Fexofen® syrup in in vitro and in vivo studies. In addition, 
pharmacokinetic parameters in permeability studies were estimated by using WinNonLin soft-
ware program. w/o microemulsion system was optimized using a pseudoternary phase diagram, 
composed of span 80/lutrol F 68 (9.5:0.5 w/w), oleic acide, isopropyl alcohol and water as sur-
factant mixture; oil and cosurfactant was developed for oral drug delivery. w/o microemulsion 
systems were characterized by phase behavior, particle size, viscosity and solubilization capacity. 
In vitro studies were studied using Caco-2 cell monolayer. Pharmacokinetic parameters of w/o 
microemulsion were investigated in rabbits and compared to Fexofen® syrup. Fexofen® syrup 
and microemulsion were administered by oral gavage at 6 mg/kg of the same concentration. 
The experimental results indicated that microemulsion (HLB = 5.53) formed nanometer sized 
droplets (33.29 ± 1.76) and had good physical stability. This microemulsion increased the oral 
bioavailability of FEX which was highly water-soluble but fairly impermeable. The relative 
bioavailability of FEX microemulsion was about 376.76% compared with commercial syrup in 
rabbits. In vitro experiments were further employed for the enhanced effect of the microemul-
sion for FEX. These results suggest that novel w/o microemulsion plays an important role in 
enhancing oral bioavailability of low permeability drugs.
Keywords: pharmacokinetic,   bioavailability, permeability, oleic acid
Introduction
Allergic rhinitis is a common disorder associated with a high incidence of   morbidity.1 
Several mediators are involved in the pathophysiology of allergic diseases, so a variety 
of drugs, including antihistamines, decongestants, intranasal corticosteroids, leukot-
riene receptor antagonists, topical anticholinergics, mast cell stabilizers,   mucolytics, 
and anti-IgE antibodies are used in the clinical treatment of allergic rhinitis.   However, 
among these mediators, antihistamine remains the principal one, and plays a funda-
mental role in the genesis of allergic rhinitis. Therefore, antihistamines have been 
the main class of medications used for the treatment of allergic rhinitis over the past 
60 years.2,3
Fexofenadine hydrochloride, the active metabolite of terfenadine, a well known and 
effective H1 receptor antagonist, is administered by the oral route. It is a   nonsedating 
antihistamine providing rapid, long-acting, and highly selective peripheral H1 receptor 
antagonist activity.4–6 The oral bioavailability of fexofenadine in humans is not   established.7 
  However, in other animals, it is known to be as low as 4.2% (in rats)7 and 2.6% (in horses).8 International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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In a review of 16 human pharmacokinetic studies, Chen et al 
reported that the half-life of fexofenadine varies between 3 
and 17 hours.9 In our study, the half-life of fexofenadine w/o 
microemulsion was significantly (P , 0.05) decreased (by 2.04-
fold) when compared with a commercial fexofenadine syrup 
(Fexofen®, Sanovel,   Istanbul, Turkey) because of differences in 
clearance rates and distribution   volumes for the two formula-
tions. In addition, the enterohepatic circulation is involved in 
the   prolonged plasma elimination half-life of fexofenadine due 
to increased oral absorption.
The efflux transporter, P glycoprotein, has been reported 
to transport fexofenadine in in vitro models. Thus, it is 
considered to be an important determinant of the pharma-
cokinetics of fexofenadine.10 Fexofenadine is a substrate for 
P glycoprotein, and concomitant food and coadministration 
of drugs have significant effects on its oral bioavailability.11 
In addition, according to the biopharmaceutical classification 
system, fexofenadine belongs to the Class 3 drugs, which 
means it has high solubility and low permeability, so an effort 
to increase the permeability of fexofenadine is needed.12
Microemulsions known to enhance bioavailability in 
the gastrointestinal tract are thermodynamically stable, iso-
tropically clear dispersions of two immiscible liquids, such 
as oil and water, and are stabilized by an interfacial film 
of surfactant molecules.13–17 Further advantages of using 
microemulsions as drug delivery systems include better drug 
solubilization and protection against enzymatic hydrolysis, 
as well as the potential for enhanced absorption due to a 
surfactant-induced increment in permeability. In addition, 
microemulsions represent an interesting and potentially quite 
powerful alternative carrier system for drug delivery because 
of their high solubilization capacity, transparency, ease of 
preparation, and high diffusion and absorption rates when 
compared with solvents without the surfactant system.18,19
In this study, we designed and developed a novel micro-
emulsion formulation to improve the oral absorption of 
fexofenadine. Absorption of fexofenadine in the intestine 
was compared with that of Fexofen syrup in vitro and in vivo 
in rabbits. In particular, Caco-2 cell permeability and the 
pharmacokinetics of the fexofenadine microemulsion were 
determined to evaluate the potential of the microemulsion to 
be an effective oral delivery carrier for drugs with bioavail-
ability problems, like fexofenadine.
Materials and methods
Materials
Fexofenadine was provided by Basel Drug Company (  Istanbul, 
Turkey). Diphenylhydramine was purchased from Sigma 
Chemical Co (St Louis, MO). Lutrol F 68 was   purchased 
from BASF (Ludwigshafen, Germany). Span 80, oleic acid, 
and   isopropyl alcohol were obtained from   Sigma-Aldrich 
(St Louis, MO). Cell culture reagents and supplies were 
obtained from Gibco Invitrogen (Grand Island, NY). Sodium 
dodecyl sulfate was purchased from Sigma Chemical Co.
Preparation of microemulsion
solubility studies
The solubility of fexofenadine in various oils and surfactants 
was determined by adding an excess amount of fexofenadine 
into 1 mL of each vehicle, followed by shaking (100 rpm) 
at 25°C for 24 hours. The samples were centrifuged at 
10000 rpm for 10 minutes to remove excess fexofenadine, 
and the concentration of fexofenadine in the supernatant 
was measured by high-performance liquid chromatography 
(HPLC) after appropriate dilution with isopropyl alcohol.
construction of pseudoternary phase diagram
Microemulsion fields formed by dilution and gentle agita-
tion were identified from ternary phase diagrams of systems 
  containing oil-surfactant (S)-cosurfactant (coS). Oleic acid 
was selected as the oil phase. The effects of surfactants (mix-
tures of span 80 and lutrol F 68 at w/w ratios of 9.5:0.5 with 
a hydrophilic-lipophilic balance of 5.53) and the cosurfactant 
(isopropyl alcohol) on the pseudoternary phase diagram 
were systematically observed at room temperature. Lutrol 
F 68 were melted at 50°C–60°C and blended with span 80 
to make the surfactant mixture. Afterwards, the oil phase 
and the surfactant mixture were mixed. The boundaries of 
the microemulsion domains were determined for different 
values of the S/coS (w/w) ratios. The S/coS weight ratios 
were 1:1, 2:1, 3:1, 4:1, and 5:1. Distilled water was added 
dropwise to each clear oil and surfactant mixture with gentle 
stirring to allow equilibration. Following addition of aliquots 
in the water phase, the mixture was examined visually for 
transparency. Based on the results of the pseudoternary 
phase diagrams, one microemulsion was selected for further 
experiments (Table 1). Thereafter, the fexofenadine-loaded 
microemulsion was prepared by adding 6 mg of fexofenadine 
per 1 mL of microemulsion with vortexing.
characterization of microemulsion
Droplet size determination
The droplet size, polydispersity, and zeta potential of the 
microemulsions (with and without fexofenadine) were 
  measured using a zeta sizer (3000 HSA, Malvern Instruments, 
Worcestershire, UK) with six measurements.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Viscosity
The viscosity of the microemulsions (with and without 
  fexofenadine) was measured at 25°C ± 0.1°C using a Brook-
field digital viscometer-III rheometer V 3.3 HB (Middleboro, 
MA) at 200 rpm (n = 6).
conductivity measurements
The effect of the amount of water phase in the microemulsions 
was monitored quantitatively by measuring electrical   conductivity. 
The water phase was added drop by drop into the mixture of oil 
phase and, after each drop of water,   electrical conductivity was 
measured using a conductometer WPA CM 35 (Cambridge, UK), 
at 25°C ± 0.1°C. The conductivity of microemulsions with and 
without fexofenadine was measured (n = 6).
ph measurements
The pH values of the samples were measured by a pH meter 
(Jenway 3040 Ion Analyze, Combined Glass Electrode, 
  Mettler-Toledo, Greifensee, Switzerland) at 25°C ± 0.1°C 
(n = 6).
hPLc analysis of fexofenadine
HPLC was used for the loading content and permeability 
studies of fexofenadine. Samples were appropriately diluted 
with isopropyl alcohol to 20 µL and injected directly into 
the HPLC system without further treatment. The HPLC 
system was equipped with a Waters 2487. A reverse phase 
C18 column (250 mm × 4 mm, 5 µm) LiChroCART® (Merck, 
Darmstadt, Germany) was used at room temperature. The 
excitation and emission wavelengths of the fluorescence 
detector were set as 220 nm and 290 nm, respectively. 
A mixture of acetonitrile and 0.05 M pH 3.2 potassium 
dihydrogen phosphate buffer solutions (60:40, v/v) was used 
as the mobile phase at a flow rate of 1.0 mL/min.
content of fexofenadine
Petroleum ether 2.5 mL was added to 200 mL of microemul-
sion containing fexofenadine and mixed for three minutes 
at 1000 rpm, followed by addition of 2.5 mL 0.05 M pH 3.2 
potassium dihydrogen phosphate buffer solution. The mixture 
was vortexed and centrifuged at 3000 rpm for 15 minutes. 
Finally, the upper liquid phase was constituted with 2.5 mL 
of mobile phase, and 20 µL was injected into the HPLC 
system (n = 6).
stability test
To evaluate the stability of the optimized formulation of 
fexofenadine, the microemulsion was put into sealed glass 
vials, which were stored at 25°C and 40°C for 6 months. The 
clarity, concentration of fexofenadine, and droplet size were 
thereafter investigated at predetermined intervals (n = 6).
Permeability studies in caco-2  
cell monolayer
cell cultures
The colonic adenocarcinoma cell line, Caco-2, was obtained 
from the American Type Culture Collection, and cultured in 
Dulbecco’s Modified Eagle Medium. The cell   monolayers 
were prepared by seeding 4 × 105 cells/well on a 6-well 
Transwell® insert filter. Cell cultures were maintained at 
37°C under 90% humidity and 5% CO2. Monolayers were 
used 19–22 days after seeding. The integrity of each cell 
monolayer was checked by measuring its transepithelial 
electrical resistance (TEER) with an epithelial Volt-Ohm 
meter (EVOM, World Precision Instrument, Sarasota, FL) 
before and after the experiments (n = 6).
Permeability of fexofenadine from microemulsion 
versus syrup
The in vitro permeability study was developed in Caco-2 cell 
monolayers grown in Transwell inserts with collagen-coated 
polycarbonate membranes having a pore size of 0.4 µm 
and a surface area of 4.7 cm2. The cells were maintained at 
37°C in the atmospheric conditions described earlier. The 
medium was replaced every second day for 3 weeks. For the 
experiment with Caco-2 cell monolayers, w/o microemul-
sion (fexofenadine 6 mg/mL) and commercial syrup (6 mg/
mL) formulations were diluted up to 95% (v/v) with Hank’s 
Buffered Salt Solution (HBSS).
The permeability studies were performed in both direc-
tions, ie, from apical to basolateral and basolateral to api-
cal. After washing the Caco-2 cell monolayer twice with 
prewarmed HBSS medium (pH 7.4), the fexofenadine 
microemulsion was diluted with HBSS (95% v/v). The 
transport experiments were done by adding the fexofena-
dine microemulsion diluted with HBSS to either the apical 
Table 1 The solubility of FeX in various vehicles at 25°c
Vehicles FEX (mg/mL)
Water 1.58 ± 0.04
Oil
  Oleic acid 6.15 ± 0.25
surfactants
  Lutrol F 68 24.95 ± 0.49
  span 80 12.28 ± 0.04
  Isopropyl alcohol 29.55 ± 0.27
Abbreviation: FeX, fexofenadine.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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(2.2 mL) or basolateral side (3.2 mL), while the receiving 
chamber contained the corresponding volume of transport 
medium. After shaking at 50 rpm for 2 hours at 37°C in a 
water bath, samples were collected from both sides of the 
Caco-2 cell monolayer and immediately stored below −20°C 
for subsequent HPLC analysis. The same procedure was used 
for the syrup formulation.
Apparent permeability values (Papp) for each side were 
calculated according to the following equation:
  Papp
dQ
dt ACo
=
1
60
  (1)
where Papp is the apparent permeability (cm/sec), dQ/dt is 
the permeation rate, A is the diffusion area of monolayers 
(cm2 ), and Co is the initial concentration of drug in the donor 
compartment.1
Pharmacokinetic studies in rabbits
study design
Two groups of rabbits (weight 1.8–2.5 kg, provided by the 
Central Animal Laboratory of Ege University) were used 
to perform the in vivo pharmacokinetic study. Six rabbits 
were allocated to each group. All rabbits were maintained 
in a light-controlled room at a temperature of 25°C ± 0.5°C. 
The experimental protocols were approved by the Animal 
Care and Use Committee of the College of Pharmacy, 
Ege University. Before the experiment, the rabbits were 
fasted overnight for 12 hours with free access to water, and 
remained conscious throughout the experiment. For the oral 
administration, the fexofenadine syrup and w/o microemul-
sion formulations were administered at the same doses by 
oral gavage (6 mg/kg body weight). Blood samples (2 mL) 
were withdrawn from the ear vein at predetermined time 
intervals (hours 0, 1, 2, 3, 4, 5, 6, 7, and 8), and 75 µL/mL of 
heparin solution was used to maintain patency of the cannula 
between sampling times. Plasma samples were obtained by 
immediately centrifuging the blood samples at 10,000 rpm 
for 10 minutes, after which 500 µL of each plasma sample 
was stored at −20°C until analyzed by HPLC.
Plasma analysis
The fexofenadine concentration in the plasma samples was 
analyzed by HPLC.20 Briefly, plasma samples (500 µL) were 
mixed with 2 µg/mL of internal standard (DFN) and 1500 µL 
of methanol. The mixture was vortexed for 10 minutes and 
centrifuged at 4000 rpm for 5 minutes at 5°C ± 0.5°C, and 
the supernatant was evaporated to dryness under nitrogen at 
40°C. The residue was reconstituted with 200 µL of mobile 
phase and injected into the HPLC system. Chromatography 
was performed using 3 µm C18 columns (100 mm × 3 mm, 
Phenomenex, Torrance, CA) at a flow rate of 0.8 mL/min 
with acetonitrile 0.02 M potassium dihydrogen phosphate 
buffer solution mixture (25:75, v/v) as the mobile phase at 
room temperature. A calibration curve was constructed in the 
range of 0.5–30 µg/mL. The mean correlation coefficient (r2) 
for the calibration curve was at least 0.999.
Pharmacokinetic analysis
The pharmacokinetic parameters for fexofenadine after 
administration of the microemulsion and syrup were calcu-
lated for each rabbit using the WinNonlin® program (Version 
3.1, Pharsight Co, Mountainview, CA). Noncompartmental 
analysis was used to calculate the peak plasma concentration, 
time taken to reach peak concentration, and the area under 
the curve (AUC). The relative bioavailability of the oral drug 
delivery system was calculated as follows:
  Relativeb ioavailability
AUCm icroemulsion
AUCs yrup
=×
()
()
100
  (2)
statistical analysis
A two-tailed unpaired Student’s t-test was performed, with 
P , 0.05 considered to be statistically significant.
Results
solubility studies
The solubility of fexofenadine in the various vehicles is 
shown in Table 1. Isopropyl alcohol was selected as a cosur-
factant for the study because it has the highest solubility 
for fexofenadine and has been reported to have a favorable 
enhancing effect on the oral bioavailability of fexofena-
dine.9 Oleic acid was chosen as the oily phase for its good 
drug solubility (Table 1). Span 80 and lutrol F 68 were 
selected as surfactants due to their ability to augment drug 
solubilization.7
construction of pseudoternary  
phase diagrams
Investigation of the phase behavior of these systems 
demonstrated that our approach was suitable for determining 
the water phase, oil phase, surfactant concentration, and 
cosurfactant concentration at which the transparent phase 
microemulsion system was formed.21 The construction of a 
phase diagram makes it easy to identify the concentration range 
of components in the microemulsions. Figure 1 shows the International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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phase diagrams constructed to determine the optimum S/coS 
concentration ratio for the formulation of w/o microemul-
sion consisting of span 80, lutrol F 68, oleic acid, isopropyl 
alcohol, and water. The S/coS and surfactant mixture (span 
80/lutrol F 68) ratios were found to be 1:1 and 9.5:0.5 for the 
optimized microemulsion. As shown in Figure 1A, the area of 
w/o microemulsion becomes enlarged and is highest at a S/coS 
ratio of 1:1. The exact composition according to oil, surfactant, 
cosurfactant, and aqueous phases is shown in Table 2.
characterization of microemulsion
The physicochemical characteristics of the microemul-
sions are shown in Table 3. Particle size analysis showed 
that the mean droplet size for the microemulsions with and 
without fexofenadine was below 100 nm. Microemulsions 
without fexofenadine were transparent colloidal dispersions 
with an average diameter of 39.05 nm and a polydispersity 
index of 0.044. When fexofenadine was loaded into the 
microemulsion system, the microemulsion did not change 
in transparency or polydispersity index value, but the mean 
droplet size decreased from 39.05 nm to 33.29 nm. A possible 
reason for this might be that the contents of the microemulsion 
and fexofenadine affect each other. When the fexofenadine 
molecule is dissolved and dispersed into the emulsifying 
membrane layer (composed of surfactant and cosurfactant) 
and oil phase, the chemical groups in the fexofenadine 
molecule can react with the other groups in the surfactant, 
cosurfactant, and oil phase, producing hydrogen bonds. This 
could be due to the decreased surface tension created by the 
presence of surfactant and cosurfactant.22 In addition, the zeta 
potential was measured. When fexofenadine was loaded to 
the microemulsion system, the zeta potential of the micro-
emulsion increased from 1.95 mV to 2 mV . This increment 
was not statistically significant (P , 0.05). It is clear from 
the physicochemical data (Table 3) that microemulsions with 
and without fexofenadine had similar values for viscosity, 
conductivity, and pH (P . 0.05).
Fexofenadine content
Table 3 shows that the fexofenadine content in the micro-
emulsion system was approximately 5.98 mg/mL. Loading 
of fexofenadine into the w/o microemulsion system was 
obtained, with an encapsulation efficiency of 99.67%.
stability test
After storage at 25°C and 40°C for 6 months, the optimized 
fexofenadine microemulsion remained clear and   transparent 
Table 2 The contents of optimized microemulsion formulation
Formulation Oil (%) S1 (%) S2 (%) coS (%) Water (%)
Microemulsion 34.05 1.49 28.31 29.79 6.36
Notes: s1: Lutrol F 68, s2: span 80, cos: Isopropyl alcohol.
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without any phase separation. Table 4 shows that the 
fexofenadine concentration and droplet size in the micro-
emulsion was not changed significantly, suggesting that the 
fexofenadine-loaded microemulsion was stable under the 
above conditions.
Permeability of fexofenadine in caco-2 
cell monolayer
Figure 2 shows the permeability profiles for fexofenadine 
from the w/o microemulsion and from the commercial 
syrup across the Caco-2 cell monolayers. The permeability 
studies were performed at 37°C. The results indicate that 
  permeability of fexofenadine from the w/o microemulsion 
was greater than that of the syrup formulation. The bidirec-
tional Papp values for both formulations are summarized in 
Table 5.
Generally, substances with an apparent   permeability coef-
ficient (Papp) , 1 × 10−6 cm/sec are classified as low perme-
ability substances, and those with an apparent   permeability 
coefficient . 1 × 10−5 cm/sec are classifed as high perme-
ability substances.7 The microemulsion and commercial syrup 
  formulations had high permeability for both directions. Papp B to A 
(permeability from basolateral to apical direction) was higher 
than Papp A to B (permeability from apical to basolateral direction) 
for both formulations, consistent with the contribution of a 
secretion transporter, and fexofenadine has been   demonstrated 
to be a P glycoprotein substrate.8 When the fexofenadine 
microemulsion was applied to the Caco-2 cell, the Papp A to B 
was increased (2.55 × 10−5 ± 0.05 cm/sec) compared with 
the Papp A to B of the syrup (1.97 × 10−5 ± 1.23 cm/sec), and the 
Papp B to A was increased (2.61 × 10−5 ± 1.77 cm/sec)   compared 
with the Papp B to A of the syrup (2.39 × 10−5 ± 1.33 cm/sec). These 
findings suggest that fexofenadine in the microemulsion has 
higher permeability than when in the commercial syrup form. 
This also indicates that the microemulsion is an enhancer of 
  fexofenadine permeability.
effect of fexofenadine on Teer across 
caco-2 cell monolayer
TEER values across Caco-2 cells have been used as indica-
tors of tight junction integrity in cell monolayers. Therefore, 
the effects of both formulations on the ability to modulate 
tight junctions could be monitored using this indicator. 
  Experiments performed with the commercial syrup showed 
a change in TEER of , 20% for 2 hours in both directions 
(apical to basolateral and basolateral to apical). However, 
experiments with the microemulsion showed a reduction in 
TEER over the 2 hours, with TEER being 33.7% and 41.1% 
of control values at 2 hours in the apical to basolateral 
and basolateral to apical directions, respectively (Table 6). 
Changes in TEER after treatment with the microemulsion 
were statistically significant compared with the commercial 
syrup (P , 0.05). In general, the microemulsion-induced 
decrease in TEER was correlated with an increase in perme-
ability of fexofenadine.
estimation of fexofenadine transport 
parameters
Fexofenadine permeability values for the microemulsion 
were higher than for the syrup in the basolateral to apical 
and apical to basolateral directions. This is consistent with 
the presence of surfactant and cosurfactant as permeability 
enhancers. The following model equations, including the 
passive diffusion component and the Michelis–Menten 
  component, were fitted to the dataset for apical to basolateral 
Table 3 characterization of microemulsion
Samples Electrical conductivity  
(μs cm−1)
Viscosity η η  
(cps)
Droplet size 
(nm)
Polydispersity Zeta potential 
(mV)
Content of FEX   
mg/mL
A 1 ± 0.03 104.7 ± 0.15 39.05 ± 0.87 0.044 ± 0.01 −1.95 ± 0.12 –
B 1.1 ± 0.02 103.8 ± 0.25 33.29 ± 1.76 0.044 ± 0.02 −2.13 ± 0.21 5.98 ± 0.17
Notes: A: Microemulsion without FeX, B: Microemulsion with FeX.
Abbreviation: FeX, fexofenadine.
Table  4  stablity  of  optimum  microemulsion  containing  FeX   
(A) and (B)
Temperature/ 
month
25°C 40°C
Droplet 
size  
(nm)
Content  
of FEX  
(mg/mL)
Droplet  
size  
(nm)
Content  
of FEX  
(mg/mL)
(A)
0 33.29 ± 0.95 5.98 ± 0.17 33.29 ± 0.95 5.98 ± 0.17
3 33.72 ± 0.61 5.89 ± 0.24 34.01 ± 0.55 6.11 ± 0.12
6 33.34 ± 0.44 6.01 ± 0.16 34.72 ± 0.85 6.09 ± 0.35
25°C 40°C
Zeta potiential (mV) Zeta potiential (mV)
(B)
0 2.13 ± 0.21 2.13 ± 0.21
3 2.1 ± 0.14 2.11 ± 0.2
6 2.01 ± 0.09 2.14 ± 0.15
Abbreviation: FeX, fexofenadine.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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and basolateral to apical permeabilities in order to estimate 
the passive component and Vm and Km.
  PP eff dif
Vm
Km C
=−
+
  (3)
  PP eff dif
Vm
Km C
=+
+
  (4)
where Peff is the experimental permeability value, Pdif is 
the passive diffusion component, and Vm and Km are the 
Michelis–Menten parameters. A second model was explored 
with the following equations:
  PP eff dif
Vm
Km C
=−
+
  (5)
  PP
A
eff dif
Vm
Km C
=+
+ *
  (6)
in which A is a correction factor included to take into account 
the fact that the binding site of the secretion carrier is located 
inside the cells so it actually “sees” a different formulation 
than the donor chamber one. This factor helps to explain why 
permeability versus concentration is not symmetrical around 
Pdif in both directions. The change in apparent permeability 
is more evident in the basal to apical direction because the 
basolateral membrane has lower resistance, and when the 
drug is applied in the basolateral chamber, the extracellular 
and intracellular concentrations are more similar than when 
the drug is placed in the apical chamber.23 The parameters 
obtained with both kinetic models for the commercial syrup 
and microemulsion are summarized in Table 7. In order to 
compare the two models, the sum of squared residuals and 
Akaike information criterion values were tabulated.
The residual variances from both fits (sum of squared/
degrees of freedom) were compared using the   Snedecor’s 
F test and an alpha value of 0.05 with the following 
equation:
  Fcalc
SSR SSR df df
SSR df
=
−− () /( )
/
12 12
22
  (7)
where SSR1 is the sum of the squared residual of the simplest 
models and SSR2 is the sum of the squared residuals of the more 
complex model, and df are the degrees of freedom of the fit 
(number of data points minus number of parameter estimated). 
The calculated F was higher than the tabulated F, indicating 
statistical significance of the more complex model, so the inclu-
sion of parameter A improves the fit to the experimental data.
Pharmacokinetic studies in rabbits
Figure 3 shows the plasma concentration-time profiles of 
  fexofenadine after administration of the w/o microemulsion 
0
03 06 0
Time (min)
A
m
o
u
n
t
 
o
f
 
F
E
X
 
(
m
 
c
g
/
m
L
)
90 120
A to B for SY
B to A for SY
A to B for ME
B to A for ME
50
100
150
200
250
300
Figure 2 The amount of FeX permeability across caco-2 cell (n = 6 ± sD).
Notes: A to B for sY = The amount of FeX from apical to basolateral direction of syrup, B to A for sY = The amount of FeX from basolateral to apical direction of syrup, 
A to B for Me = The amount of FeX from apical to basolateral direction of microemulsion, B to A for Me = The amount of FeX from basolateral to apical direction of 
microemulsion.
Abbreviations: A, apical; B, basolateral; FeX, fexofenadine; Me, microemulsion; sD, standard deviation; sY, syrup.
Table 5 The permeability value of FeX with different formulations (n = 6 ± sD)
Formulation Papp A to B 10−5(cm/s) Papp B to A 10−5(cm/s) Papp B to A/Papp A to B ratio
sY 1.97 ± 0.23 2.39 ± 0.77 1.21
Me 2.55 ± 0.05 2.61 ± 1.33 1.02
Abbreviations: A, apical; B, basolateral; FeX, fexofenadine; Me, microemulsion; sD, standard deviation; sY, syrup.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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and the syrup to rabbits, each at a dose of 6 mg/kg body weight 
(n = 6). Table 8 shows the pharmacokinetic parameters for 
fexofenadine that were evaluated by the noncompartmental 
method using the oral WinNonLin program. In this study, 
oral administration of w/o microemulsion in lower doses 
gave significantly higher peak plasma concentrations and 
AUC values compared with the syrup. The mean peak fex-
ofenadine concentration in the group treated with the syrup 
was 1.97 µg/m; a higher mean peak value of 18.63 µg/mL 
was obtained in the group treated with the microemulsion. 
This difference was statistically significant (P , 0.05). In 
the case of oral administration, the mean residence time and 
time to peak plasma concentrations obtained from the w/o 
microemulsion were significantly prolonged (P , 0.05) when 
compared with those for the syrup.
There have been many previous attempts at estimating 
the absolute oral bioavailability of fexofenadine, with val-
ues ranging widely from 10% to 90%.24 For example, Chen 
found that the absolute bioavailability of fexofenadine was 
35%.9 In this study, the relative bioavailability related to 
the AUC0→8 of fexofenadine was found to be 376.76% in 
w/o microemulsion compared with the syrup. This may be 
because the microemulsion allows the drug to be retained 
long enough in the gastrointestinal system to be well 
permeated in the gastrointestinal mucosa. According to the 
relative bioavailability value, the amount of fexofenadine in 
the microemulsion can be reduced, enabling a lower-dose 
formulation. Furthermore, a higher relative bioavailability, 
delayed mean residence time, and extended time to peak 
concentration with the fexofenadine microemulsion 
  suggested that this microemulsion could have extended-
release characteristics, and might be useful for extended-
release oral formulations of fexofenadine.
Discussion
The minimum absolute oral bioavailability of fexofenadine in 
this study was 10%–15%, based on the amount of unchanged 
drug appearing in the urine.9 Extrapolation from animal 
data is unreliable, with oral bioavailability being 2%–4% in 
rodents25 and only marginally higher at 6.6% in monkeys.26 
An estimate of 30% bioavailability in man has been made 
Table 7 Parameters of the fit of the models with passive component an Michaelis–Menten component and goodness of fit indexes
SY Value SD CV% ME Value SD CV%
Pdif (cm/s) 2.24e-05 8.79e-08 3.92 Pdif (cm/s) 3.51 e-05 6.55 e-08 2.13
Km (µM) 681.5 260.56 38.23 Km (µM) 89345 310.42 36.17
Vm (nMol· cm−2· s−1) 0.0132 0.000405 30.69 Vm (nMol ⋅ cm−2 ⋅ s−1) 0.0452 0.001105 23.46
ssr 1.30e-11 ssr 1.8e-11
AIc −1046 AIc −1087
Parameter Value SD CV% Parameter Value SD CV%
Pdif (cm/s) 2.57e-05 1.23e-07 4.77 Pdif (cm/s) 3.42 e-05 0.92 e-07 5.22
Km (µM) 513.91 160.38 31.21 Km (µM) 634.76 145.87 25.29
Vm (nMol· cm−2· s−1) 0.0147 0.000391 26.48 Vm (nMol ⋅ cm−2 ⋅ s−1) 0.0521 0.000198 27.81
A 2.79 0.86 30.82 A 3.11 0.56 25.31
ssr 9.10e-12 ssr 10.08e-12
AIc −1059 AIc −1098
Abbreviations: A, apical; B, basolateral; AIC, Akaike’s information criteria; CV, coefficient of variability; ME, microemulsion; Pdif, passive diffusion component; SD, standard 
deviation; ssr, sum of squared residuals; sY, syrup.
Note: Vm and Km are the Michaelis–Menten parameters.
Table  6  The  %  Teer  change  of  experiments  across  caco-2 
cell for both directions with ± sD (A → B: Apical to basolateral 
direction, B → A basolateral to apical direction)
% TEER Change
SY ME
A → B B → A A → B B → A
−12.8 ± 0.23 −14.7 ± 0.88 −33.7 ± 2.76 −41.1 ± 3.21
Abbreviations: A, apical; B, basolateral; Me, microemulsion; sD, standard deviation; 
sY, syrup; Teer, transepithelial electrical resistance.
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Figure  3  comparison  of  the  plasma  concentration  values  obtained  after 
administration of FeX loaded microemulsion and Fexofen®syrup.
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based on two observations,9 one being the 10% recovery 
in urine after oral fexofenadine and the other the finding 
that fexofenadine is formed by the metabolism of orally 
administered terfenadine (which is rapidly and extensively 
metabolized), and is assumed to occur systemically.
To improve its oral bioavailability, some absorption 
enhancers can be used to improve the oral absorption of 
fexofenadine, such as chitosan, sodium deoxycholate, and 
sodium dodecyl sulfate.27 However, these enhancers can lead 
to irritation of the intestinal tract, resulting in substantial dam-
age to the intestinal mucosa.28 Thus, it is hoped that a suitable 
pharmaceutical formulation of fexofenadine can be developed 
to improve intestinal absorption without damaging the intes-
tinal tissue. Our w/o microemulsion system with surfactant 
and cosurfactant has the ability to form microemulsions, 
with good biological acceptance, which is the main reason 
for their use.29 Water-soluble drugs are solubilized in w/o 
microemulsion and incorporated mainly in the water-phase 
core and therefore are released rather slowly.30 In this study, 
the viscosity, refractive index, particle size, zeta potential, and 
electric conductivity of the microemulsion were   investigated. 
The results demonstrated successful formation of a w/o 
microemulsion containing oil, surfactant/cosurfactant, and an 
aqueous phase. The optimal w/o microemulsion, consisting of 
oleic acid, lutrol F-68, span 80, and isopropyl alcohol, is a prom-
ising formulation for increasing absorption of   fexofenadine by 
the oral route and could also increase the oral bioavailability of 
other drugs with low permeability. There are several barriers to 
the oral delivery of such drugs, including luminal enzymatic 
hydrolysis, low solubility, and low membrane permeability.31,32 
Fexofenadine has good stability against enzymatic hydrolysis 
and at different pH values.33 For fexofenadine, low membrane 
permeability is the main barrier to its oral absorption. 
However, because of its good solubility, significantly improved 
absorption and bioavailability was found for fexofenadine 
after oral administration of the w/o microemulsion than with 
the commercial syrup formulation in rabbits.
Conclusion
A  novel  fexofenadine-loaded  microemulsion  was 
designed to improve the oral absorption of fexofenadine. 
The microemulsion system for fexofenadine was developed 
by construction of a pseudoternary phase diagram. The 
optimal formulation was as follows: 34.05% oil (oleic acid), 
30% surfactant (span 80/lutrol F 68), 29.79% cosurfactant 
(isopropyl alcohol), and 6.16% distilled water. The optimized 
microemulsion was characterized according to viscosity, 
solubility, content of fexofenadine, conductivity, polydisper-
sity, droplet size, and stability. In vitro and in vivo studies in 
Caco-2 cells and in rabbits showed that the microemulsion 
had significantly improved permeability across Caco-2 cells, 
a higher peak concentration and AUC, and shorter elimina-
tion half-life compared with the commercial syrup. Overall, 
the results indicate that the microemulsion was effective for 
enhancing the oral absorption of fexofenadine, and fexofen-
adine-loaded microemulsion demonstrates great potential for 
clinical application.
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